The following are some of the stocks that lost the largest percentage in price today in the pharma/biotech sector.
1. Cellular Biomedicine Group Inc. (CBMG)
Lost 10.67% to close Thursday’s (Jan.11) trading at $18.00.
News: No news
Cellular Biomedicine is a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases.
The Company currently has ongoing CAR-T phase I clinical trials in China; CARD-1 for Diffuse Large B-cell Lymphoma (DLBCL) and Non-Hodgkin Lymphoma (NHL), CALL-1 for adult Acute Lymphoblastic Leukemia (ALL), and a phase I trial in China for AlloJoin (CBMG’s “Off-the-Shelf” Allogeneic Human Adipose-derived Mesenchymal Stem Cell) for the treatment of Knee Osteoarthritis.
— Top line data readout from phase I clinical trials for CARD-1 and CALL-1 Chimeric Antigen Receptor (CAR) T-cell treatment for Diffuse Large B-Cell Lymphoma (DLBCL) and Acute Lymphoblastic Leukemia (ALL) in the first half of 2018.
— Final data readout from AlloJoin phase I clinical trial for off-the-shelf Knee Osteoarthritis (KOA) therapy in China in the first half of 2018.
2. Arena Pharmaceuticals Inc. (ARNA)
Lost 9.24% to close Thursday’s trading at $35.77.
News: No news
The advanced clinical programs are Ralinepag, which has completed a Phase 2 trial for pulmonary arterial hypertension (PAH), Etrasimod in Phase 2 evaluation for multiple autoimmune indications, and APD371 in Phase 2 evaluation for the treatment of pain associated with Crohn’s disease. The Company is also collaborating with Axovant Sciences Ltd. (AXON) for the development of Nelotanserin, which is under phase II study in subjects with Dementia with Lewy Bodies (DLB) or Parkinson’s Disease Dementia (PDD).
On January 8, 2018, the Company reported results from a pilot phase II study of Nelotanserin for visual hallucinations in Lewy body dementia and Parkinson’s disease dementia. The results…